Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · Jan 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method using a special probe called 68Ga-DOTA-BPP to help doctors see how triple-negative breast cancer (TNBC) behaves in patients. The trial aims to understand how well this imaging technique can predict cancer characteristics and help with diagnosis and staging. Participants will undergo a type of scan known as PET/CT, which combines two imaging techniques to give detailed pictures of the body.

To participate in this study, individuals must be between 18 and 75 years old and have a confirmed diagnosis of triple-negative breast cancer. They should be in relatively good health, as indicated by a specific performance score (ECOG score 0 or 1). Unfortunately, those who are pregnant, have severe liver or kidney problems, or cannot follow the imaging procedures will not be eligible. If you join the trial, you’ll receive the PET/CT scan, and researchers will analyze the images to gather important information about your cancer. This research may help improve how doctors diagnose and treat TNBC in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18-75 years old;
• • 2. ECOG score 0 or 1 point;
• • 3. Participants with confirmed TNBC cancer who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
• Exclusion Criteria:
• • 1. Pregnant or nursing;
• • 2. Severe hepatic or renal dysfunction;
• • 3. Low WBC (less than 3 x 10\^9/L);
• • 4. Unable to comply with the PET/CT imaging procedures